AZD 0284
Alternative Names: AZD-0284Latest Information Update: 02 Jun 2022
At a glance
- Originator AstraZeneca
- Class Antipsoriatics; Small molecules
- Mechanism of Action Nuclear receptor subfamily 1 group F member 3 inverse agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Plaque psoriasis; Respiratory tract disorders
Most Recent Events
- 01 Jan 2022 Discontinued - Phase-I for Plaque psoriasis (In volunteers) in United Kingdom (IV) (AstraZeneca pipeline, February 2022)
- 01 Jan 2022 Discontinued - Phase-I for Plaque psoriasis (In volunteers) in United Kingdom (PO) (AstraZeneca pipeline, February 2022)
- 01 Jan 2022 Discontinued - Phase-I for Plaque psoriasis in Denmark (PO) (AstraZeneca pipeline, February 2022)